Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

There are few scientific methods more elegantly simple than "just sprinkle it on top." Researchers at Tohoku University and ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

Researchers are making ever more sophisticated mini organs in the lab — and now they can grow their own blood vessels. The ...

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.

A new study has found that psilocin—a compound produced in the body after consuming psilocybin, the active ingredient in psychedelic mushrooms—extended the lifespan of human skin and lung cells in the ...

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated ...

Title: CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation in Neurodegenerative Disease: A Phase 1 Study to Investigate the Safety, Tolerability, and ...